Cargando…

GRADE-ing the Benefit/Risk Equation in Food Immunotherapy

PURPOSE OF REVIEW: We reviewed the existing evidence base to desensitisation for food allergy, applying the Grading of Recommendations, Assessment, Development and Evaluation approach to discuss whether desensitisation is likely to become part of routine treatment for patients with food allergy. REC...

Descripción completa

Detalles Bibliográficos
Autores principales: Duca, Bettina, Patel, Nandinee, Turner, Paul J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6483945/
https://www.ncbi.nlm.nih.gov/pubmed/31025125
http://dx.doi.org/10.1007/s11882-019-0862-6
_version_ 1783414034002870272
author Duca, Bettina
Patel, Nandinee
Turner, Paul J.
author_facet Duca, Bettina
Patel, Nandinee
Turner, Paul J.
author_sort Duca, Bettina
collection PubMed
description PURPOSE OF REVIEW: We reviewed the existing evidence base to desensitisation for food allergy, applying the Grading of Recommendations, Assessment, Development and Evaluation approach to discuss whether desensitisation is likely to become part of routine treatment for patients with food allergy. RECENT FINDINGS: Desensitisation for food allergy to peanut, egg and cow’s milk is efficacious, but whether such interventions are cost-effective is less clear, due to the issues over a sustained desensitisation effect and the increase in allergic reactions occurring in patients on treatment. Few studies have assessed the change in health-related quality of life associated with treatment, and most have not considered discordance between parent-reported changes in health-related quality of life (HRQL) outcomes compared to those of the patients themselves; none to date have controlled for the improvement in HRQL occurring after initial challenge which will confound outcomes. SUMMARY: The lack of longer-term safety and cost-effectiveness data, as well as an absence of current consensus in the reporting of patient-relevant outcomes, must be addressed in order to be able to recommend the introduction of desensitisation as a routine treatment in healthcare systems.
format Online
Article
Text
id pubmed-6483945
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-64839452019-05-15 GRADE-ing the Benefit/Risk Equation in Food Immunotherapy Duca, Bettina Patel, Nandinee Turner, Paul J. Curr Allergy Asthma Rep Immunotherapy and Immunomodulators (B Vickery, Section Editor) PURPOSE OF REVIEW: We reviewed the existing evidence base to desensitisation for food allergy, applying the Grading of Recommendations, Assessment, Development and Evaluation approach to discuss whether desensitisation is likely to become part of routine treatment for patients with food allergy. RECENT FINDINGS: Desensitisation for food allergy to peanut, egg and cow’s milk is efficacious, but whether such interventions are cost-effective is less clear, due to the issues over a sustained desensitisation effect and the increase in allergic reactions occurring in patients on treatment. Few studies have assessed the change in health-related quality of life associated with treatment, and most have not considered discordance between parent-reported changes in health-related quality of life (HRQL) outcomes compared to those of the patients themselves; none to date have controlled for the improvement in HRQL occurring after initial challenge which will confound outcomes. SUMMARY: The lack of longer-term safety and cost-effectiveness data, as well as an absence of current consensus in the reporting of patient-relevant outcomes, must be addressed in order to be able to recommend the introduction of desensitisation as a routine treatment in healthcare systems. Springer US 2019-04-25 2019 /pmc/articles/PMC6483945/ /pubmed/31025125 http://dx.doi.org/10.1007/s11882-019-0862-6 Text en © The Author(s) 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Immunotherapy and Immunomodulators (B Vickery, Section Editor)
Duca, Bettina
Patel, Nandinee
Turner, Paul J.
GRADE-ing the Benefit/Risk Equation in Food Immunotherapy
title GRADE-ing the Benefit/Risk Equation in Food Immunotherapy
title_full GRADE-ing the Benefit/Risk Equation in Food Immunotherapy
title_fullStr GRADE-ing the Benefit/Risk Equation in Food Immunotherapy
title_full_unstemmed GRADE-ing the Benefit/Risk Equation in Food Immunotherapy
title_short GRADE-ing the Benefit/Risk Equation in Food Immunotherapy
title_sort grade-ing the benefit/risk equation in food immunotherapy
topic Immunotherapy and Immunomodulators (B Vickery, Section Editor)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6483945/
https://www.ncbi.nlm.nih.gov/pubmed/31025125
http://dx.doi.org/10.1007/s11882-019-0862-6
work_keys_str_mv AT ducabettina gradeingthebenefitriskequationinfoodimmunotherapy
AT patelnandinee gradeingthebenefitriskequationinfoodimmunotherapy
AT turnerpaulj gradeingthebenefitriskequationinfoodimmunotherapy